“Sosei Group Corporation (“Sosei”) (TOKYO:4565) confirms the plan to be announced later today by Novartis at a “Meet Novartis Management” investor event in Boston, USA to develop a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medi
“Sosei Group Corporation (“Sosei”) (TOKYO:4565) confirms the plan to be announced later today by Novartis at a “Meet Novartis Management” investor event in Boston, USA to develop a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medi
このブックマークにはスターがありません。
最初のスターをつけてみよう！
Planned Development of Inhaled Triple Therapy QVM149 for Asthma
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／